Pockros, Paul J <br/><br/>
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  Aug 2008 
 - 385-97 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.22357  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alanine Transaminase--blood<br/>Antiviral Agents--administration & dosage<br/>Cytidine--analogs & derivatives<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Resistance, Viral<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>Female<br/>Hepacivirus--enzymology<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--adverse effects<br/>Male<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Nucleosides--administration & dosage<br/>Polyethylene Glycols--adverse effects<br/>Prodrugs--administration & dosage<br/>RNA, Viral--antagonists & inhibitors<br/>Recombinant Proteins<br/>Ribavirin--adverse effects<br/>Treatment Outcome<br/>Viral Load